Kevin Korenblat

Medicine & Life Sciences

1. Liver Transplantation 100%
2. Liver 98%
3. Non-alcoholic Fatty Liver Disease 71%
4. Fibrosis 68%
5. Hepacivirus 56%
6. Liver Diseases 51%
7. Transjugular Intrahepatic Portasystemic Shunt 46%
8. very low density lipoprotein triglyceride 36%
9. Kinetics 34%
10. Hepatorenal Syndrome 32%
11. Transplants 31%
12. Triglycerides 28%
13. Adipose Tissue 28%
14. Fatty Acids 26%
15. Tissue Donors 26%
16. Alzheimer Disease 26%
17. International Normalized Ratio 26%
18. Insulin 25%
19. Fatty Liver 24%
20. Kidney 23%
21. 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 23%
22. Portal Hypertension 22%
23. Guidelines 22%
24. Transplant Recipients 21%
25. Graft Survival 21%
26. 2-acylglycerol O-acyltransferase 21%
27. Chronic Renal Insufficiency 20%
28. velpatasvir 20%
29. Virus Diseases 19%
30. Placebos 19%
31. lipine 19%
32. obeticholic acid 19%
33. Heterogeneous-Nuclear Ribonucleoprotein K 18%
34. Hemorrhage 18%
35. Insulin Resistance 18%
36. Ribavirin 18%
37. sofosbuvir drug combination ledipasvir 18%
38. Lipoproteins 17%
39. Sofosbuvir 17%
40. Terlipressin 17%
41. Gastric Bypass 17%
42. Hepatopulmonary Syndrome 17%
43. Yeast Artificial Chromosomes 16%
44. Liver Neoplasms 16%
45. Yttrium-90 16%
46. Eukaryotic Initiation Factor-4E 16%
47. Weight Loss 16%
48. Therapeutics 16%
49. Surgical Portasystemic Shunt 16%
50. Fat Necrosis 15%